RNS Number:5571V
Lombard Medical Technologies PLC
13 December 2005



           Lombard Medical Technologies PLC commences trading on AIM



London, UK, 13 December 2005: Lombard Medical Technologies PLC ("Lombard" or the
"Company"), a developer of stent grafts and other medical products, announces
that trading will commence today on the AIM market of the London Stock Exchange
at 8:00am under the ticker symbol LMT.  The nominated adviser and broker to the
Company and agent in relation to the placing is Code Securities Limited.


The commencement of trading follows the placing of 16,466,359 new Ordinary
Shares at 159 pence per Ordinary Share, raising gross proceeds for the Company
of #26.2 million (#23.9 million, net of expenses).  A total of 48,893,590
Ordinary Shares will be in issue on admission, giving a market capitalisation
immediately following admission of #77.7 million.


Alistair Taylor, Executive Chairman of Lombard, commented:


"We are very pleased to have completed our IPO on AIM.  With the proceeds from
the flotation, we now look forward to commencing final pivotal clinical trials
of our AorfixTM stent graft in the key US market, for which conditional approval
has been given by the FDA."


Enquiries:


Lombard Medical Technologies PLC

Tel: 01235 750 800

Alistair Taylor, Executive Chairman

Brian Howlett, Chief Executive Officer



Code Securities Limited

Tel: 020 7776 1200

Juliet Thompson

Richard Potts



Financial Dynamics

Tel: 020 7831 3113

David Yates / John Gilbert


Notes to editors

Lombard Medical Technologies is a medical devices company developing stent
grafts and other medical products for use in the treatment of vascular disease.
The Company's lead product, AorfixTM, is a stent graft for the treatment of
aortic aneurysms, a balloon-like enlargement of the aorta which, if untreated,
may rupture and cause death.  Abdominal and thoracic aortic aneurysms are the
13th largest cause of death in the US and the market is estimated to be worth
approximately US$2 billion by 2010.  AorfixTM is currently being commercialised
in the EU, with US clinical trials expected to commence during 2006.  The
Company has a strategic collaboration with one of the world's leading medical
devices companies, Boston Scientific.


Lombard Medical has recently successfully completed its initial public offering
on AIM and was admitted to listing in December 2005, raising #23.9 million, net
of expenses.  The Company, based in Oxfordshire & Yorkshire, currently employs
47 people.


Further background on the Company can be found at www.lombardmedical.com.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCGLBDDXDBGGUX
Lombard Medical Technologies (LSE:LMT)
Historical Stock Chart
From Jul 2024 to Jul 2024 Click Here for more Lombard Medical Technologies Charts.
Lombard Medical Technologies (LSE:LMT)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Lombard Medical Technologies Charts.